ValiRx (LSE:VAL) has narrowed its losses and lifted its cash balance after a summer fundraising, but the early-stage life sciences group continues to flag a material uncertainty over its ability to continue as a going concern. In its half-year report for the six months to 30 June 2026, published on 15 September, the company set out progress across its cancer research subsidiaries alongside the mixed outcome of several asset evaluations.
What the Company Does
ValiRx describes itself as a life science company focused on early-stage cancer therapeutics and women's health. Its model is to source promising academic or early commercial assets, evaluate them and then develop selected programmes through dedicated subsidiaries. These include Inaphaea BioLabs, which runs a biobank of patient-derived cells and offers drug-evaluation services; CytoLytix, which is developing the CLX001 oncolytic peptide; Blue Ribbon Bio, home to a prostate cancer programme known as VAL201 2.0; and a newly formed ValiRx Animal Health subsidiary aimed at cancer in companion animals. The board summarises its approach as seeking to "dilute the asset not the Plc".
Latest Developments
The past few months have brought a series of announcements. On 1 June 2026 ValiRx exercised its option to negotiate an exclusive licence for an oral RNA helicase inhibitor evaluated with McGill University and IRICoR, with a new Canadian entity, after the evaluation finished ahead of schedule. By contrast, evaluations with the University of Dundee and StingRay Bio did not meet the criteria for licensing, and rights reverted to the partners.
On the intellectual property front, CytoLytix was granted a European patent covering its original nanoparticle formulation in May 2026, and on 10 August the European Patent Office indicated its intention to grant a patent covering a polyleucine peptide. Inaphaea has established new commercial agreements with The Christie NHS Foundation Trust and is developing ovarian cancer models, while management reported "green shoots" in commercial interest in its patient-derived cell models.
Financial Picture
ValiRx remains pre-revenue in practical terms, recording just £1,300 of revenue in the half. The loss before tax narrowed to £826,958 from £931,135 a year earlier, helped by lower administrative expenses, and the loss per share fell to 0.09p from 0.22p, reflecting the larger share count. Cash was £970,564 at 30 June 2026, up from £791,612 at the end of 2025.
That improvement followed a June fundraising of about £1.155m through a placing, a subscription by directors and a retail offer, all priced at 0.2p per share. Warrants exercisable at 0.28p were issued alongside. The directors said they expect to seek further funding through grants, subsidiary-level financing and, if needed, equity, but no binding commitments are in place.
Sector and Index Context
ValiRx is among the smallest healthcare companies in the FTSE AIM All Share Index. Early-stage drug developers on AIM have faced a challenging funding environment, with many relying on frequent, heavily discounted placings to finance research, and ValiRx's sub-penny share price reflects that pressure.
Key Risks
Funding is the dominant risk, as highlighted by the going concern uncertainty. Further equity raises at low prices could cause significant dilution. Scientific and commercial outcomes are uncertain, as shown by the two evaluations that did not progress, and the company's value depends on securing licensing deals or external investment in its subsidiaries.
What to Watch Next
Management expects internal testing for its Altus Formulation evaluation to begin in the fourth quarter of 2026, along with readouts on an Inaphaea grant application tied to its drug-screening accelerator. Investors will also be watching for the outcome of licence negotiations on the McGill asset, progress in talks with venture capital investors for the subsidiaries, and any further fundraising.






Please wait processing your request...